HTTIF (HighTide Therapeutics) 1-Year Sharpe Ratio: N/A (As of Jul. 06, 2026)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.39
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-06), HighTide Therapeutics's 1-Year Sharpe Ratio is Not available.

HighTide Therapeutics  (OTCPK:HTTIF) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

HighTide Therapeutics 1-Year Sharpe Ratio Related Terms

HTTIF vs VRTX, REGN, ALNY: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, HighTide Therapeutics's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HighTide Therapeutics 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's 1-Year Sharpe Ratio falls into.


HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HighTide Therapeutics 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price